Help us now

Research lab

Research Team

Thierry Passeron co-leads with Dr. Stéphane Rocchi an INSERM research team at the Mediterranean Center for Molecular Medicine in Nice. The theme of this team is: "Study of the melanocyte differentiation applied to the patient's vitiligo and melanoma with molecular mechanisms".

Research team

INSERM U1065, team 12, C3M

The Mediterranean center of molecular medicine (C3M) gather 13 research teams with more than 160 researchers. The thematics of the center are cell proliferation and cell death; differentiation and cancer; metabolic disorders; interactions of micro-organisms. Within this center, our team (see adjacent picture) study melanoma and pigmentary disorders with a special interest for vitiligo. The conducted studies are very translational, meaning that they usually start from clinical observations and from patient samples to better understand the mechanisms involved in vitiligo. The objective of these researches is not only to better understand the disease but mostly to discover new therapeutic approaches that we can then propose to our patients.

N E W S

Ruxolitinib cream (Opzelura) has just obtained reimbursement in France.It will initially be direct access, that is to say that all dermatologists will be able to prescribe itbut it will have to be picked up initially from hospital pharmacies.

Numerous ongoing and future trials for diffuse vitiligo(at least 5% of the face AND 5% of the body affected).

Research lab

Research Team

Research team

Ruxolitinib cream (Opzelura) has just obtained reimbursement in France.
It will initially be direct access, that is to say that all dermatologists will be able to prescribe it
but it will have to be picked up initially from hospital pharmacies.

Numerous ongoing and future trials for diffuse vitiligo
(at least 5% of the face AND 5% of the body affected).